


Product Details

· · · · · · · · · · · · · · · · · · ·		
Size	100 μL	
Species Reactivity	Human, Mouse, Xenopus	
Published Species	Human	
Host/Isotype	Mouse / IgG2a	
Class	Monoclonal	
Туре	Antibody	
Conjugate	Unconjugated	
Immunogen	Raised against the largest subunit of RNA polymerase II of wheat germ and interacts with the highly conserved C-terminal domain of this protein containing the repeat YSPTSPS.	
Form	Liquid	
Concentration	Conc. Not Determined	
Storage buffer	ascites	
Contains	<0.1% sodium azide	
Storage conditions	-20° C, Avoid Freeze/Thaw Cycles	
RRID	AB_2533882	


Applications	Tested Dilution	Publications
Western Blot (WB)	1:500-1:1,000	-
Immunocytochemistry (ICC/IF)	1:100	-
ChIP assay (ChIP)	1-10 µL/1x10^6 cells	2 Publications
ChIP-sequencing (ChIP-Seq)	2 µL/1x10^6 cells	-

1



RNA pol II CTD Antibody (49-1033) in ChIP-seq

ChIP was performed on sheared chromatin from 1 million HeLaS3 cells using 2 μ L of the anti-Pol II antibody (Product # 49-1033). The IP'd DNA was subsequently analysed on an Illumina HiSeq. Library preparation, cluster generation and sequencing were performed according to the manufacturer's instructions. The 51 bp tags were aligned to the human genome using the BWA algorithm. The figure shows the enrichment along the complete sequence and a 1 Mb region of the X-chromosome (fig A and B) and in genomic regions of chromosome 12 and 3, surrounding the GAPDH and EIF4A2 positive control genes (fig C and D).




RNA pol II CTD Antibody (49-1033) in WB

Western blot was performed using Anti-RNA pol II CTD Monoclonal Antibody (Product # 49-1033) and a 250 kDa band corresponding to -RNA pol II was observed across cell lines tested. Nuclear enriched extracts (40 µg lysate) of HeLa (Lane 1), MCF7 (Lane 2), Jurkat (Lane 3), HCT 116 (Lane 4), DU 145 (Lane 5), LNCaP (Lane 6) and Raji (Lane 7) were electrophoresed using NuPAGE[™] 3-8% Tris-Acetate Protein Gel (Product # EA0378BOX). Resolved proteins were equilibrated with 20% ethanol and then transferred onto a nitrocellulose membrane (Product # IB23001) by iBlot® 2 Dry Blotting System (Product # IB21001). The blot was probed with the primary antibody (1:1000 dilution) and detected by chemiluminescence with Goat anti-Mouse IgG (H+L) Superclonal[™] Recombinant Secondary Antibody, HRP (Product # A28177,1: 20000 dilution using the iBright[™] FL1500 Imaging System (Product # A44115). Chemiluminescent detection was performed using SuperSignal[™] West Pico PLUS Chemiluminescent Substrate (Product # 34580).

RNA pol II CTD Antibody (49-1033) in ICC/IF

Immunofluorescence analysis of RNA pol II CTD Monoclonal Antibody was performed using 70% confluent log phase HCT 116 cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton[™] X-100 for 15 minutes, and blocked with 2% BSA for 45 minutes at room temperature. The cells were labeled with RNA pol II CTD Monoclonal Antibody (Product # 49-1033) at 1:100 dilution in 0.1% BSA, incubated at 4 degree celsius overnight and then labeled with Donkey anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor Plus 488 (Product # A32766), (1: 2000 dilution), for 45 minutes at room temperature (Panel a: Green). Nuclei (Panel b:Blue) were stained with ProLong[™] Diamond Antifade Mountant with DAPI (Product # P36962). F-actin (Panel c: Red) was stained with Rhodamine Phalloidin (Product # R415, 1:300 dilution). Panel d represents the merged image showing Nuclear localization. Panel e represents control cells with no primary antibody to assess background. The images were captured at 60X magnification.

View more figures on thermofisher.com



2

2 References

ChIP assay (2)

Cell death & disease Year 2022 Regulatory mechanisms and function of hypoxia-induced long noncoding RNA NDRG1-OT1 in breast cancer cells. Species Human "49-1033 was used in Chromatin immunoprecipitation to reveal novel regulatory mechanisms of NDRG1-OT1 by HIF-1 and upon miR-875-3p. Also, NDRG1-OT1 promoted the malignancy of breast cancer cells and encoded a small peptide. Authors: Chao HH,Luo JL,Hsu MH,Chen LH,Lu TP,Tsai MH,Chuang EY,Chuang LL,Lai LC Genes & cancer Year 2016 The adenoviral E1A N-terminal domain represses MYC transcription in human cancer cells by targeting both p300 and TRRAP and inhibiting **Species** Human MYC promoter acetylation of H3K18 and H4K16.

"49-1033 was used in ChIP assay identify host pathways targeted by viral E1A 1-80 using cancer cells" Authors: Zhao LJ,Loewenstein PM,Green M

For Research Use Only, Not for use in diagnostic procedures. Not for resale without express authorization. Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, this warranty is specifications and/or accompanying package inserts ("Documentation"). No claim of suitability for use in applications represent that any Product specifications in effect at the time of sale, as set forth in the Production documentation, this warranty are used to a sample furnished to Buyer is merely illustrative of the general type and quality of goods and does not represent that any Product will conform to such model or sample. NO OTHER WARRANTES, EXPRESS OR INVELD, VAR GRANTED INCLUDING WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICLAR PURPOSE, OR NON INFRINGEMENT. BUYER'S EXCLUSIVE ENterboy FOR NON-CORRING PRODUCTS JUNING THE WARRANTES NO EXPRESS OR INVERDING CLUDING WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICLAR PURPOSE, OR NON INFRINGEMENT. BUYER'S EXCLUSIVE ENterboy FOR NON-CORRING PRODUCTS JUNING THE WARRANTE NO CLUDING WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICLAR TO A REGULATION TO REPARI, REPLACE OR REFUND FOR THE NON-CONFORMING PRODUCTS SOLED OFTION. THERE IS NO OBLICATION TO REPARI, REPLACE OR REFUND FOR THE NON-CONFORMING PRODUCTS SOLED OFTION. THERE IS NO BULGATION TO REPARI, REPLACE OR REFUND FOR THE NON-CONFORMING PRODUCTS AS THE RESULT OF (I) ACCIDENT, DISASTER OR EVENT OF FORCE MAJEURE, (III) USE OF THE PRODUCTS IN A MANKER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS IN A MANKER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS IN A MANKER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND IN A BUYER, (III) USE OF THE PRODUCTS IN A MANKER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPR